Back to Journals » OncoTargets and Therapy » Volume 11

MiR-411 suppresses the development of bladder cancer by regulating ZnT1

Authors Liu Y, Liu T, Jin H, Yin L, Yu H, Bi J

Received 10 May 2018

Accepted for publication 3 September 2018

Published 4 December 2018 Volume 2018:11 Pages 8695—8704


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Yao Dai

Yang Liu, Tao Liu, Hongwei Jin, Lei Yin, Hongyuan Yu, Jianbin Bi

Urology Surgery, First Affiliated Hospital of China Medical University, Shenyang, China

Background: At present, the molecular genetics of the development and progression of bladder cancer are still unclear. In recent years, the pathological relevance and significance of microRNAs (miRNAs) in bladder cancer have attracted increasing attention.
Methods: The expressions of miR-411 and zinc transporter 1 (ZnT1) in bladder cancer were determined by western blot and real-time PCR. Biological software, luciferase reporter gene, Western blot and real-time PCR were used to determine the regulatory effect of miR-411 on ZnT1. MTT and transwell were used to confirm the regulatory effect of miR-411 on bladder cancer cells. MTT and transwell were used to find how miR-411 modulated the biological activity of bladder cancer cells by regulating ZnT1.
Results: The expression of miR-411 was low in bladder cancer and was negatively correlated with ZnT1. MiR-411 can inhibit the activity and the expression of ZnT1. MiR-411 can inhibit the growth and metastasis of bladder cancer cells. MiR-411 inhibited the growth and metastasis of bladder cancer cells by targeting ZnT1.
Conclusion: The miR-411 target ZnT1 may provide a potential therapeutic target for the treatment of bladder cancer.

Keywords: miR-411, ZnT1, bladder cancer, proliferation, metastasis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]